Contineum Therapeutics - CTNM STOCK NEWS

Contineum Therapeutics (NASDAQ: CTNM) has appointed Diego Miralles, M.D. to its Board of Directors, effective March 14, 2025. Dr. Miralles, currently CEO of AZURNA Therapeutics, brings extensive experience in novel therapy development and clinical trials.

Dr. Miralles' career includes leadership roles at Laronde Inc. (2020-2022), Vividion Therapeutics (2017-2020), and Johnson & Johnson (2007-2016). He currently serves on the board of Artiva Biotherapeutics and chairs its Clinical Strategy Committee. His academic background includes an M.D. from the University of Buenos Aires, residency at Mayo Clinic, and fellowship at The New York Hospital/Cornell University.

Contineum, a clinical-stage biopharmaceutical company, focuses on developing therapies for neuroscience, inflammation, and immunology (NI&I) indications. The company is preparing to initiate multiple proof-of-concept clinical trials.

Contineum Therapeutics (NASDAQ: CTNM), a clinical-stage biopharmaceutical company focused on developing therapies for neuroscience, inflammation and immunology (NI&I) conditions, has announced its upcoming participation at the Stifel 2025 Virtual CNS Forum.

The company's management will deliver a presentation on Tuesday, March 18th at 12:30 p.m. ET. Interested parties can access the audio webcast through the Investors section of Contineum's website, where a replay will also be made available.

Contineum Therapeutics (NASDAQ: CTNM) has reported its Q4 2024 financial results and clinical development milestones. The company ended Q4 2024 with $204.8 million in cash and equivalents, projecting runway through 2027.

Key upcoming milestones include:

• PIPE-791 Phase 1b PET trial topline data expected in Q2 2025
• PIPE-307 Phase 2 VISTA trial data for RRMS treatment anticipated in H2 2025
• Phase 2 proof-of-concept trials for IPF and PrMS planned for H2 2025
• PIPE-791 Phase 1b chronic pain trial topline data expected in early 2026

Financial highlights show R&D expenses at $13.0 million (62% increase YoY), G&A expenses at $4.0 million, and a net loss of $14.6 million for Q4 2024.

Contineum Therapeutics (NASDAQ: CTNM) has initiated patient dosing in a Phase 1b trial for PIPE-791, a novel brain penetrant small molecule antagonist targeting chronic pain treatment. The randomized, double-blind, placebo-controlled, crossover trial will evaluate the drug's safety, tolerability, and pain reduction effectiveness.

The study focuses on chronic pain associated with osteoarthritis (OA) and low back pain (LBP). The trial will enroll approximately 40 patients across five U.S. sites, with a 28-day treatment duration. Topline data is expected in early 2026.

PIPE-791 works by blocking the lysophosphatidic acid 1 receptor (LPA1R), potentially modifying maladaptive changes in the central nervous system associated with chronic pain. The drug aims to provide a non-opioid treatment alternative for patients suffering from OA and LBP.

Contineum Therapeutics (NASDAQ: CTNM), a clinical-stage biopharmaceutical company focused on developing therapies for neuroscience, inflammation and immunology (NI&I) conditions, has announced its upcoming participation at the 2025 Leerink Partners Global Healthcare Conference.

The company's management will deliver a presentation on Tuesday, March 11th at 3:00 p.m. ET. Interested parties can access the audio webcast through the Investors section of Contineum's website, where a replay will also be made available.

Contineum Therapeutics (NASDAQ: CTNM) has completed enrollment of 168 patients in its Phase 2 PIPE-307 VISTA trial for treating relapsing-remitting multiple sclerosis (RRMS). The trial, designed to assess safety and efficacy, will evaluate multiple clinical and imaging endpoints sensitive to remyelination changes in RRMS patients.

PIPE-307, being developed under a global license agreement with Janssen Pharmaceutica NV, is positioned as a potentially first-in-class M1 receptor antagonist. The Phase 2 study is randomized, double-blind, placebo-controlled, and multi-center. The last patient is expected to complete the trial in Q3 2025, with enrollment completion achieved ahead of schedule in December 2024.

Contineum Therapeutics (NASDAQ: CTNM) has initiated patient dosing in its Phase 1b PET trial for PIPE-791, a novel brain penetrant small molecule antagonist targeting the LPA1 receptor. The open-label, single-center trial aims to evaluate receptor occupancy in the brain and lungs of multiple patient cohorts, including healthy volunteers, idiopathic pulmonary fibrosis (IPF), and progressive multiple sclerosis (PrMS) patients.

The study will measure the correlation between pharmacokinetics and receptor occupancy using PET imaging. The company expects to release topline data in the second quarter of 2025. The trial is registered under NCT06683612.

Contineum Therapeutics (NASDAQ: CTNM), a clinical stage biopharmaceutical company developing oral small molecule therapies for neuroscience, inflammation and immunology conditions, has announced its participation in the 7th Annual Evercore HealthCONx Conference. The company's management will engage in a fireside chat on December 4, 2024, at 11:15 a.m. ET in Miami. The event will be accessible via audio webcast through Contineum's website's Investors section, with a replay option available.

Contineum Therapeutics (NASDAQ: CTNM) received FDA authorization for its IND application for PIPE-791, targeting chronic pain treatment. The company plans to commence a Phase 1b study in Q1 2025 for osteoarthritis and low back pain treatment. The study will be randomized, double-blind, placebo-controlled, involving approximately 40 patients across five sites with a 28-day treatment duration. Topline data is expected in early 2026. PIPE-791 is a novel brain penetrant small molecule antagonist of LPA1R, targeting neuropathic pain components. The company's cash position of $213.9 million is expected to fund operations through 2027.